Depression levels and interferon treatment in people with multiple sclerosis.
Multiple sclerosis (MS) is the most common cause of neurologic disease in young and middle-aged adults, and 75% of patients are female. Nearly one in two patients with MS will experience clinically significant depression-approximately three times the prevalence rate in the general population. This study used a cross-sectional approach to examine the link between depression levels and use of interferon medications among individuals with MS. Data were collected from 694 patients of the Multiple Sclerosis Comprehensive Care Center at Holy Name Medical Center in Teaneck, New Jersey. Analysis of variance was used to compare depression scores between patients taking and not taking interferons. Regression analyses with depression scores as the dependent variable were also conducted. The Beck Depression Inventory (BDI) was reduced to a set of dimensions by principal components analysis. Two components were identified, reflecting somatic and cognitive symptoms. The results showed no significant relationship between depression levels and interferon treatment. Significant associations were observed between depression and both age and disability status, with younger, more disabled patients tending to be more depressed.
Ferkauf School of Psychology, Yeshiva University, Bronx, NY, USA (SK, FWF, VZ); Multiple Sclerosis Comprehensive Care Center, Holy Name Medical Center, Teaneck, NJ, USA (SK, FWF, MAP); and Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (JH).
Sonya
S
Kim
Ferkauf School of Psychology, Yeshiva University, Bronx, NY, USA (SK, FWF, VZ); Multiple Sclerosis Comprehensive Care Center, Holy Name Medical Center, Teaneck, NJ, USA (SK, FWF, MAP); and Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (JH).
Frederick W
FW
Foley
Ferkauf School of Psychology, Yeshiva University, Bronx, NY, USA (SK, FWF, VZ); Multiple Sclerosis Comprehensive Care Center, Holy Name Medical Center, Teaneck, NJ, USA (SK, FWF, MAP); and Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (JH).
Mary Ann
MA
Picone
Ferkauf School of Psychology, Yeshiva University, Bronx, NY, USA (SK, FWF, VZ); Multiple Sclerosis Comprehensive Care Center, Holy Name Medical Center, Teaneck, NJ, USA (SK, FWF, MAP); and Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (JH).
June
J
Halper
Ferkauf School of Psychology, Yeshiva University, Bronx, NY, USA (SK, FWF, VZ); Multiple Sclerosis Comprehensive Care Center, Holy Name Medical Center, Teaneck, NJ, USA (SK, FWF, MAP); and Consortium of Multiple Sclerosis Centers, Hackensack, NJ, USA (JH).
Vance
V
Zemon